The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021.

HIV-1 drug resistance is a huge challenge in the era of ART. To investigate the prevalence and characteristics of acquired HIV-1 drug resistance (ADR) in Shanghai, China. An epidemiological study was performed among people living with human immunodeficiency virus (PLWH) receiving ART in Shanghai from January 2017 to December 2021. A total of 8669 PLWH were tested for drug resistance by genotypic resistance testing. Drug resistance mutations (DRMs) were identified using the Stanford University HIV Drug Resistance Database program. Ten HIV-1 subtypes/circulating recombinant forms (CRFs) were identified, mainly including CRF01_AE (46.8%), CRF07_BC (35.7%), B (6.4%), CRF55_01B (2.8%) and CRF08_BC (2.4%). The prevalence of ADR was 48% (389/811). Three NRTI-associated mutations (M184V/I/L, S68G/N/R and K65R/N) and four NNRTI-associated mutations (V179D/E/T/L, K103N/R/S/T, V106M/I/A and G190A/S/T/C/D/E/Q) were the most common DRMs. These DRMs caused high-level resistance to lamivudine, emtricitabine, efavirenz and nevirapine. The DRM profiles appeared to be significantly different among different subtypes. We revealed HIV-1 subtype characteristics and the DRM profile in Shanghai, which provide crucial guidance for clinical treatment and management of PLWH. © The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Citation

Min Zhang, Yingying Ma, Gang Wang, Zhenyan Wang, Qianying Wang, Xin Li, Feng Lin, Jianping Qiu, Daihong Chen, Yinzhong Shen, Chiyu Zhang, Hongzhou Lu. The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. The Journal of antimicrobial chemotherapy. 2024 Mar 01;79(3):526-530

Mesh Tags

Substances

PMID: 38300833

search → result